汇添富健康生活一年持有A业绩表现较为突出。 2025年以来的震荡市场中，沪深300指数下跌3.76%，汇添富健康生活一年持有A仍保持36.03%的正收益，跑赢 业绩比较基准超过30个百分点，同类排名34/4575。 重仓股科伦博泰生物、百利天恒年内股价涨幅超四成 汇添富健康生活一年持有基金经理为张韡。公开资料显示，张韡曾任东方证券医药助理研究员，汇添富基金医 药研究员、高级医药研究员及医药行业研究组组长。 截至2025年4月23日数据（下同），该基金近一年收益率达29.23%，成立以来回报率达到16.67%，大幅跑赢业 绩比较基准及同类平均。 基金经理张韡在行业分化中抓住结构性机会，成为近年来健康主题基金的领跑者。2025年以来，基金净值累计 上涨36.03%，同类排名34/4575。 业绩领跑：年内回报达36.03% 汇添富健康生活一年持有A成立于2021年3月，基金采用自下而上的投资方法，以深入的基本面分析为立足点， 精选健康生活主题中的优质上市公司，在科学严格管理风险的前提下，谋求基金资产的中长期稳健增值。 基金业绩比较基准为中证医药卫生指数收益率*50%+中证消费服务领先指数收益率*20%+中债综合指 ...

Core Viewpoint - The A-share market shows mixed performance with the largest consumption ETF (159928) experiencing fluctuations, reflecting a strong capital allocation interest in the consumer sector, with a net inflow of nearly 2.8 billion yuan over the past 60 days [1][5]. Group 1: ETF Performance and Market Trends - The consumption ETF (159928) has seen a trading volume exceeding 250 million yuan, with a premium widening to 0.12% during the trading session, indicating investor interest [1]. - The ETF's underlying index has achieved record high profits, with a net profit of 191.9 billion yuan in the first three quarters of last year, representing a year-on-year growth of 29.44% [5]. - As of April 23, the consumption ETF (159928) has a total share count exceeding 19.1 billion, maintaining a historical high [5]. Group 2: Sector Analysis - Within the food and beverage sector, the white liquor segment has seen an increase in fund holdings, with the proportion of heavy holdings remaining the highest among sectors [5]. - Factors contributing to the increased allocation in the white liquor sector include improved consumer spending intentions, overall valuation uplift, and expected sales growth post-2024 [5]. - The top ten constituent stocks of the consumption ETF account for 67% of its weight, with five leading liquor stocks comprising 36% [8]. Group 3: Future Outlook - Analysts expect a strengthening of policies in May, which may benefit the consumer sector, particularly in light of recent macroeconomic meetings and a relatively loose capital environment [5]. - The consumption ETF's valuation remains attractive, with a price-to-earnings ratio of 20.66, placing it in the bottom 1.98% of its valuation range over the past decade [5].

中银创新医疗混合A股票持仓前十占比合计70.44%，分别为：科伦博泰生（9.77%）、恒瑞医药 （9.39%）、信达生物（8.54%）、康方生物（8.24%）、康诺亚-B（6.59%）、新诺威（6.27%）、百济 神州-U（6.02%）、百利天恒（5.89%）、和黄医药（5.16%）、翰森制药（4.57%）。 金融界2025年4月23日消息，中银创新医疗混合A(007718) 最新净值1.6795元，下跌1.12%。该基金近1个 月收益率18.94%，同类排名9|4629；近3个月收益率42.92%，同类排名15|4571；今年来收益率39.57%， 同类排名21|4554。 简历显示：郑宁先生:中国,研究生、硕士。曾任泰康资产管理有限责任公司股票研究经理、高级股票研 究经理;中庚基金管理有限公司研究员、高级研究员(医药组组长)。2022年加入中银基金管理有限公司。 2022年7月1日担任中银创新医疗混合型证券投资基金基金经理。2022年10月13日担任中银医疗保健灵活 配置混合型证券投资基金基金经理。2023年2月28日任中银大健康股票型证券投资基金基金经理。 来源：金融界 公开资料显示，中银创新医疗混合A ...

■■■10■■■■■■■■■■■■ ■■■■■■■■■■■■ 96632.59■■■■■■■■■■■ 77.49%■■■■■■■ 521.61■■■ | ■■ | ■■■■(■■) | ■■■■■■(%) | ■■■■(■■) | | --- | --- | --- | --- | | ■■■■■■■■■■■■■ | 87863.94 | 70.46 | 229.47 | | ■■■■■■■■■■ | 1595.42 | 1.28 | -72.12 | | ■■■■■■■■A | 1220.00 | 0.98 | ■■ | | ■■■■■■■■■■■■ | 1158.72 | 0.93 | ■■ | | ■■■■■601066■■■■■■■■■ | 1024.94 | 0.82 | -103.15 | | ■■■■■■ETF | 951.86 | 0.76 | -74.98 | | ■■■■■■■■■■■■■■-■■■■■■■■■■ | 790.00 | 0.63 | ■■ | | ■■■■■■■■■■■A | 719.04 | 0.58 | ■■ | | ■■■■■■■002173■■■A | 682.06 ...

Financial Performance - The company's revenue for Q1 2025 was ¥471,967,670.63, representing a decrease of 9.94% compared to ¥524,066,868.93 in the same period last year[5]. - The net profit attributable to shareholders for Q1 2025 was a loss of ¥26,901,607.29, a decline of 134.03% from a profit of ¥79,061,260.62 in Q1 2024[5]. - Total operating revenue for the current period was ¥471,967,670.63, a decrease of 9.9% compared to ¥524,066,868.93 in the previous period[22]. - The company reported a net profit of -142,361,032.21 yuan for the current period, compared to a net profit of 29,961,530.26 yuan in the previous period, indicating a significant decline[23]. - Operating profit for the current period was -126,574,064.46 yuan, while the previous period showed an operating profit of 56,155,547.90 yuan, reflecting a substantial decrease[23]. - The total comprehensive income for the current period was -142,313,442.07 yuan, compared to 29,589,098.69 yuan in the previous period[23]. - Basic and diluted earnings per share for the current period were both -0.0192 yuan, down from 0.0676 yuan in the previous period[23]. Cash Flow and Liquidity - The net cash flow from operating activities improved significantly, with a net outflow of ¥86,799,597.52, a 91.10% reduction compared to a net outflow of ¥975,365,408.34 in the previous year[12]. - Cash and cash equivalents at the end of the period reached ¥1,298,752,857.02, up 48.9% from ¥872,081,872.91 at the beginning of the period[19]. - The company reported cash and cash equivalents at the end of the period amounting to 1,298,752,857.02 yuan, a decrease from 2,686,302,001.07 yuan at the end of the previous period[26]. - The company generated cash inflow from investment activities amounting to 472,270,137.70 yuan, with a net cash flow from investment activities of 361,108,752.50 yuan[26]. - The company recorded a total operating cash inflow of 443,386,291.36 yuan, down from 576,280,891.81 yuan in the previous period[25]. - The company received 163,000,000.00 yuan from financing activities, resulting in a net cash flow from financing activities of 163,000,000.00 yuan[26]. Assets and Liabilities - The total assets at the end of Q1 2025 were ¥6,092,264,108.12, reflecting a 1.16% increase from ¥6,022,115,755.32 at the end of the previous year[5]. - Total assets increased to ¥6,092,264,108.12, compared to ¥6,022,115,755.32 at the beginning of the period, reflecting a growth of 1.2%[20]. - Total liabilities rose to ¥1,734,625,266.13, an increase of 13.7% from ¥1,526,185,458.97 in the previous period[20]. - The company's total equity decreased to ¥4,357,638,841.99 from ¥4,495,930,296.35, a decline of 3.1%[21]. - The company’s total equity attributable to shareholders decreased by 0.66% to ¥3,705,741,472.18 from ¥3,730,544,275.59 at the end of the previous year[5]. Research and Development - Research and development expenses surged by 117.68% to ¥240,479,825.00 in Q1 2025, up from ¥110,476,228.75 in Q1 2024, due to multiple products being in clinical development[11]. - Research and development expenses surged to ¥240,479,825.00, representing a significant increase from ¥110,476,228.75 in the previous period[22]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 11,564[14]. - The largest shareholder, Shijiazhuang Yiling Pharmaceutical Co., Ltd., holds 73.77% of shares, totaling 1,036,159,894 shares[14]. - The company has 157,520,510 restricted shares held by Shijiazhuang Yiling Pharmaceutical Co., Ltd., which are subject to a 36-month transfer restriction[16]. - The total number of shares held by the top 10 unrestricted shareholders is 878,639,384 shares[14]. - The company has not disclosed any changes in the top 10 shareholders due to margin trading activities[15]. - The company has not reported any changes in the number of preferred shareholders or their holdings[15]. - The company’s stock structure includes various institutional investors, with the top 10 shareholders holding a significant portion of the shares[14]. - The company’s financial disclosures indicate a commitment to transparency regarding shareholder relationships and potential risks associated with stock transfers[17]. Acquisition Plans - The company plans to acquire 100% equity of Shijiazhuang Baike Biopharmaceutical Co., Ltd. through a combination of cash and stock issuance, with the transaction currently under review by the Shenzhen Stock Exchange[17]. - The company will continue to provide updates on the acquisition process as it progresses through regulatory reviews[17].

新诺威（300765）公告，2025年第一季度营收为4.72亿元，同比下降9.94%；净亏损2690.16万元，去年 同期净利润7906.13万元。 ...

Core Insights - The latest net value of the Fuqua Precision Medical Mixed A fund is 2.9019 yuan, reflecting a growth of 3.48% [1] - The fund has shown significant performance with a one-month return of 18.27%, a three-month return of 30.86%, and a year-to-date return of 30.23%, ranking 8th out of 1502, 10th out of 1497, and 14th out of 1492 in its category respectively [1] Fund Holdings - The top ten stock holdings of the Fuqua Precision Medical Mixed A fund account for a total of 69.71%, with the largest positions being: - Baillie Gifford (9.66%) - Haisco (9.65%) - Kelun Pharmaceutical (9.10%) - Huatai Medical (9.05%) - Zai Lab (7.84%) - Heng Rui Medicine (5.95%) - Innovent Biologics (5.29%) - Sinovac Biotech (5.11%) - BeiGene (4.91%) - Zhaoke Pharmaceutical (3.15%) [1] Fund Management - The Fuqua Precision Medical Mixed A fund was established on November 16, 2017, and as of March 31, 2025, it has a total asset size of 3.746 billion yuan, managed by Zhao Wei [1]

金融界2025年4月22日消息，工银前沿医疗股票A(001717) 最新净值2.9210元，增长1.67%。该基金近1个 月收益率7.75%，同类排名38|1014；近3个月收益率12.82%，同类排名84|1007；今年来收益率11.02%， 同类排名80|1001。 工银前沿医疗股票A股票持仓前十占比合计59.05%，分别为：恒瑞医药（10.11%）、科伦药业 （8.01%）、药明康德（7.72%）、百济神州-U（6.85%）、信立泰（4.90%）、泽璟制药-U （4.77%）、鱼跃医疗（4.60%）、新诺威（4.36%）、华东医药（4.20%）、海思科（3.53%）。 来源：金融界 公开资料显示，工银前沿医疗股票A基金成立于2016年2月3日，截至2025年3月31日，工银前沿医疗股 票A规模90.81亿元，基金经理为赵蓓。 简历显示：赵蓓女士:硕士,曾在中再资产管理股份有限公司担任投资经理助理。2010年加入工银瑞信,现 任研究部副总监、医疗保健研究团队负责人,2014年11月18日至今,担任工银医疗保健行业股票型基金基 金经理;2015年4月28日至今,担任工银瑞信养老产业股票型基金基金经理;201 ...

Group 1 - The A-share market showed divergence with the Shanghai Composite Index rebounding and surpassing 3300 points, marking an 8-day consecutive rise, while the Shenzhen Component and ChiNext Index declined [1] - The logistics, cross-border payment, free trade port, unified market, and diversified finance sectors surged due to the release of two significant policy documents aimed at enhancing the Shanghai International Financial Center [5] - Pharmaceutical stocks rebounded, particularly in the innovative drug sector, with several leading companies reaching historical highs, such as BaiLi TianHeng, which rose by 11.41% to a market capitalization of 116.9 billion [5] Group 2 - Multiple pharmaceutical companies reported positive developments in clinical trials for innovative drugs, including HengRui Medicine's approval for two clinical trials and XinLiTai's acceptance of a clinical trial application for a gene-editing drug [5] - Industry analysis indicates that Chinese innovative drug companies possess significant advantages in research efficiency and cost control, leading to faster drug development and higher potential returns for investors [6] - The consumer sector was active, with retail and duty-free shop stocks rising, highlighted by GuoFang Group hitting the daily limit for the 13th time in 12 trading days [6]

医药板块持续走高 众生药业等多股涨停 智通财经4月22日电，午后医药板块持续走高，创新药方向继续领涨，众生药业、华森制药、富士莱涨 停，百利天恒、诺诚健华、新诺威、百济神州创历史新高，复旦张江、上海谊众、信立泰、热景生物等 涨幅靠前。消息面上，4月25日至4月30日，美国癌症研究协会（AACR）年会将在芝加哥召开。作为全 球规模最大的癌症研究会议之一，AACR年会一直是癌症领域最新研究成果的重要展示平台。 ...